Program
T3D-959
Also written as “15mg T3D-959”, “30 mg T3D-959” and “45 mg T3D-959”.
Its studies are mostly in Alzheimer Disease, led by T3D Therapeutics.
Furthest: phase 3, since Apr 14, 20253 company-led studies, 1 open or runningNext primary completion: Apr 2031 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| T3D Therapeutics | 31 open or running | phase 3since Apr 14, 2025 | Jul 28, 2015 | Apr 2031phase 3 · NCT06964230 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2015First study: phase 2 study in Alzheimer DiseaseFirst studyNCT02560753 · 36 enrolled · United States
- Jan 24, 2020Phase 2 study in Alzheimer DiseaseNCT04251182 · 250 enrolled · United States
- Apr 14, 2025Phase 3 study in Alzheimer DiseaseNCT06964230 · 376 planned · United States
Ahead
- Apr 2031Primary completion: phase 3 study in Alzheimer DiseaseNCT06964230
TargetBeta
“Peroxisome proliferator-activated receptor delta agonist; Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06964230Alzheimer Disease · United States | 3 | Not yet recruiting | Apr 2031 | 376 |
| NCT04251182Alzheimer Disease · United States | 2 | Completed | Jan 20, 2023 | 250 |
| NCT02560753Alzheimer Disease · United States | 2 | Completed | May 30, 2016 | 36 |
How it is read
Names in the registry
- “T3D-959”, 2 entries
- “15mg T3D-959”, 1 entry
- “30 mg T3D-959”, 1 entry
- “45 mg T3D-959”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.